Launch Date
05/04/2022
Credit Amount
1.50 Hours
Credit Expires
05/04/2023
Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease, with a highly variable phenotypic expression that ranges from no symptoms to drug-refractory heart failure. HCM is a lifelong condition that can worsen over time and is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Patients may go years without a diagnosis despite being symptomatic, putting them at increased risk for atrial fibrillation, stroke, heart failure, and sudden cardiac death.
To provide the best quality of care and achieve optimal outcomes, it is critical for clinicians to properly screen appropriate patients and determine the etiology of symptoms, which are often non-specific. Genetic testing can help determine if the hypertrophy is associated with mutations in one of several sarcomeric genes which encode components of the contractile apparatus of the heart.
In this CME Outfitters OnDemand symposium from Heart Rhythm 2022, three experts in HCM explore the latest strategies and updates in HCM diagnosis and management, including progress with disease-specific treatments that target cardiac myosin.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Bristol Myers Squibb.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in cardiology and electrophysiology
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. [Hard return + divider]
Dr. Abraham reports no financial relationships.
Dr. Ommen reports no financial relationships.
Dr. Ho reports the following financial relationships: Advisory Board: Bristol Myers Squibb. Consultant: Tenaya Therapeutics. Research: Pfizer Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.
Call us at 877.CME.PROS (877.263.7767).
MMV-122-050422-08